GLP-1s in a More Mode: More Indications, More Access | Predictions for 2025
Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.
The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 diabetes and obesity. Recent breakthroughs in research for sleep apnea, polycystic ovarian syndrome, Parkinson’s disease and more have demonstrated their potential.
Twelves
In the coming year, patients will have greater access to these medications than ever before. We’ll see more and more providers integrating GLP-1s into their patients’ treatment plans, indications across various therapeutic areas, and, subsequently, more payers offering coverage for them.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
